Jean-Marc D. Quach
President and CEO
Jean-Marc Quach is the President and Chief Executive Officer of The Alpha-1 Project, Inc. responsible for overall coordination and management activities. Prior to joining The Alpha-1 Project, Inc., his most recent position was Vice President at Bayer Diabetes Care responsible for… managed care, durable medical equipment marketing, reimbursement, government, and contracts.
Prior to Bayer, he was with Express Scripts Inc., where he held various leadership roles in line and staff positions from 1998 to 2006. He was the Vice-President of Strategic Planning and Market Analysis from 2004 to 2006. As the Vice-President and General Manager of the Express Scripts Specialty Distribution Services subsidiary, he presided over the growth of a start-up to a $100 million entity. He also worked at NYLCare Health Plans (now Aetna) as its director of pharmacy, and at American Express Company.
He earned his B.A. in International Business Administration (Magna Cum Laude) from the American University of Paris, in Paris, France, and an M.B.A. from Harvard Business School.
Karen L. Erickson
Chief Operating Officer
Karen Erickson is the Chief Operating Officer of The Alpha-1 Project, Inc. and recently served as the Associate Executive Director of Community Engagement at the Alpha-1 Foundation. Prior to her position on staff, she held voluntary positions of service in the alpha-1 antitrypsin deficiency (AATD) and rare disease and disability communities.
Erickson held a management position at Amgen and specialized in performance management in Clinical Operations. Karen has extensive experience in protein science, with particular interest in drug product characterization, formulation and manufacturing. She has experience in both clinical product/process development and commercial product sustainment activities and has held related leadership positions in both the U.S. and international arenas. Karen held an expat position in portfolio and technology transfer at Trinity Biotech, Bray, Co. Wicklow, Ireland.
She was co-founder and Chair of Ability Bettered through Leadership and Education (ABLE), an affinity group commissioned to improve the quality of life of Amgen employees and community members who were differently challenged by disease or conditions. She represented the Alpha-1 Foundation on the steering committee of Clinical Trials Transformation Initiative and was an elected member of the American Thoracic Society Public Advisory Roundtable, serving on the Clinicians Advisory, Awards and Drug/Device Discovery and Development Committees in that capacity. Karen was elected and served as Co-Chair of the Coalition of Patient Advocacy Groups (CPAG) at NCATS and was recently selected to serve on the newly formed FDA Patient Engagement Collaborative (PEC).
Prior to accepting her role as COO of TAP, Karen served on the TAP Scientific and Business Advisory Council.